Mylan reaches $4.5m settlement with Maryland over EpiPen prices
( May 4, 2026, 22:31 GMT | Official Statement) -- MLex Summary: Mylan has agreed to pay $4.5 million to resolve resolving concerns brought by the Maryland Attorney General about anticompetitive conduct involving the cost, marketing, and availability of EpiPen products. Maryland claimed that Mylan took steps to protect its market dominance and suppress competition, by entering into exclusionary contracts with pharmacy benefit managers that blocked generic competitors, filing patent lawsuits against competitors and then entering into pay-for-delay settlements, and lodging unfounded concerns with the Food and Drug Administration about EpiPen generic competitors in order to delay the availability of those lower-cost alternatives.Statement follows in full. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.